The AAN, Child Neurology Society (CNS), Epilepsy Foundation (EF), American Epilepsy Society (AES), and the National Association of Epilepsy Centers (NAEC) are working with Questcor Pharmaceuticals, Inc. to address concerns over pricing of H.P. Acthar Gel (ACTH) used in the treatment of infantile spasms.
At an October 11 meeting, the Academy, along with its partner organizations met with Questcor representatives to discuss their recent decision to significantly increase the drug's cost.
The meeting was convened in response to a letter written on behalf of the five organizations that focused mainly on patient access to medication.
Questcor outlined a response which encouraged physicians to contact them if their patients are being denied access or payment to ACTH. Questcor is currently working with hospital pharmacies to ensure availability and provide alternative stocking mechanisms, including the ability for pharmacies to return unused vials. In addition, the company is considering developing a physician advisory group and either a joint, or separate, hospital pharmacy advisory committee. Physicians are advised to contact Questcor for further information on assistance that may be available to help patients.
The AAN is closely following this issue. For more information, contact Rod Larson at email@example.com.